Drug intelligence / Profile preview

SCH BT2

Development stage: Preclinical
Modality: Small Molecules
Administration: Intrastriatal Infusion

Overview

SCH BT2 is a water-soluble analogue of SCH 58261, functioning as an adenosine A2A receptor antagonist. Preclinical studies have investigated its potential in treating motor deficits associated with Parkinson's disease, demonstrating its ability to reduce parkinsonian tremor in rat models.

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on SCH BT2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCH BT2.

Explore the full profile